Answers are grounded in this paper and cite their sources.
Diagnostic development study demonstrates rapid cystatin C detection in human serum using a microfluidic electrochemical immunosensor, suggesting strong potential for point-of-care kidney monitoring.
Chronic kidney disease (CKD) is a progressive disorder characterized by structural and functional alterations in the kidneys arising from various etiologies. Cystatin C (Cys C) is regarded as a superior endogenous biomarker because it is less affected by confounding factors such as age and gender. In this work, an electrochemical immunosensor was developed for Cys C detection by electropolymerizing o‐phenylenediamine (OPD) on the electrode surface via cyclic voltammetry (CV) to form poly(o‐phenylenediamine) (PoPD). The PoPD layer not only accelerated electron‐transfer kinetics but also provided a favorable matrix for antibody immobilization. The immunosensor achieved a limit of detection (LOD) of 186.88 ng mL −1 and a linear range of 500–6000 ng mL −1 , while exhibiting satisfactory reproducibility, specificity, and operational stability. Spike recovery studies and direct analysis of human serum samples verified the practical performance of the proposed sensor. A low‐cost, portable microfluidic electrochemical device was developed for serum Cys C quantification. The integration of electrochemical sensing with the microfluidic platform offers low sample consumption, simplified operation, fast detection, and promising potential for POCT.
No takes yet. Share an insight, caveat, or question.
He et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: